Taysha Gene Therapies (NASDAQ:TSHA) Given New $8.00 Price Target at Canaccord Genuity Group

Taysha Gene Therapies (NASDAQ:TSHA) had its target price upped by Canaccord Genuity Group from $6.00 to $8.00 in a report issued on Friday morning,Benzinga reports. Canaccord Genuity Group currently has a buy rating on the stock.

A number of other research firms also recently issued reports on TSHA. Chardan Capital reaffirmed a “buy” rating and set a $7.00 price target on shares of Taysha Gene Therapies in a research note on Thursday. Needham & Company LLC reissued a “buy” rating and issued a $6.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday. Finally, JMP Securities reiterated a “market outperform” rating and issued a $5.00 target price on shares of Taysha Gene Therapies in a research report on Tuesday. Eight research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $6.63.

Taysha Gene Therapies Stock Down 9.3 %

Shares of NASDAQ:TSHA traded down $0.21 during midday trading on Friday, reaching $2.06. The company’s stock had a trading volume of 7,298,813 shares, compared to its average volume of 2,617,602. The company has a quick ratio of 5.22, a current ratio of 5.22 and a debt-to-equity ratio of 0.35. The firm has a 50 day moving average of $1.98 and a 200-day moving average of $2.38. Taysha Gene Therapies has a 12-month low of $1.19 and a 12-month high of $4.32. The firm has a market capitalization of $422.18 million, a P/E ratio of 3.27 and a beta of 0.44.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TSHA. Bank of New York Mellon Corp bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $1,018,000. Creative Planning bought a new position in Taysha Gene Therapies in the third quarter valued at about $28,000. SG Americas Securities LLC acquired a new stake in Taysha Gene Therapies during the 3rd quarter valued at approximately $129,000. Rhumbline Advisers acquired a new position in shares of Taysha Gene Therapies during the 2nd quarter valued at $413,000. Finally, Scientech Research LLC acquired a new stake in shares of Taysha Gene Therapies in the 2nd quarter worth about $97,000. Institutional investors own 77.70% of the company’s stock.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.